Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT04949113 |
Title | Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma (NADINA) |
Acronym | NADINA |
Recruitment | Active, not recruiting |
Gender | |
Phase | Phase III |
Variant Requirements | No |
Sponsors | The Netherlands Cancer Institute |
Indications | |
Therapies | |
Age Groups: | adult | child | senior |
Covered Countries | USA | NLD | AUS |